StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$13.62+0.77 (+5.99%)

Close on Nov 18, 2026Market cap $182.28MP/E –Yield –

Anika Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Anika Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$5.12M. For fiscal 2025 it was -$11.05M. The highest annual figure on record is $61.45M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.05M–
FY2024Dec 31, 2024-$5.10M-704.4%
FY2023Dec 31, 2023$844.00K-77.0%
FY2022Dec 31, 2022$3.67M+40.3%
FY2021Dec 31, 2021$2.62M–
FY2020Dec 31, 2020-$28.32M-182.7%
FY2019Dec 31, 2019$34.25M+57.5%
FY2018Dec 31, 2018$21.75M-52.4%
FY2017Dec 31, 2017$45.73M-9.6%
FY2016Dec 31, 2016$50.61M+5.1%
FY2015Dec 31, 2015$48.13M-21.7%
FY2014Dec 31, 2014$61.45M+88.4%
FY2013Dec 31, 2013$32.61M+65.4%
FY2012Dec 31, 2012$19.72M+41.2%
FY2011Dec 31, 2011$13.97M+85.3%
FY2010Dec 31, 2010$7.54M+34.9%
FY2009Dec 31, 2009$5.59M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.95M–
Q1 FY2026Mar 31, 2026-$5.49M–
Q4 FY2025Dec 31, 2025$646.00K–
Q3 FY2025Sep 30, 2025-$3.23M–
Q2 FY2025Jun 30, 2025-$4.18M–
Q1 FY2025Mar 31, 2025-$4.28M–
Q4 FY2024Dec 31, 2024-$705.00K-102.9%
Q3 FY2024Sep 30, 2024-$81.00K–
Q2 FY2024Jun 30, 2024-$1.81M–
Q1 FY2024Mar 31, 2024-$2.51M–
Q4 FY2023Dec 31, 2023$24.70M+50.6%
Q3 FY2023Sep 30, 2023-$7.67M–
Q2 FY2023Jun 30, 2023-$3.63M–
Q1 FY2023Mar 31, 2023-$12.55M–
Q4 FY2022Dec 31, 2022$16.40M–
Q3 FY2022Sep 30, 2022-$5.80M-546.0%
Q2 FY2022Jun 30, 2022-$3.38M-136.8%
Q1 FY2022Mar 31, 2022-$3.55M-382.5%
Q4 FY2021Dec 31, 2021-$9.12M–
Q3 FY2021Sep 30, 2021$1.30M–
Q2 FY2021Jun 30, 2021$9.18M–
Q1 FY2021Mar 31, 2021$1.26M-82.3%
Q4 FY2020Dec 31, 2020-$17.95M-473.9%
Q3 FY2020Sep 30, 2020-$7.93M-165.8%
Q2 FY2020Jun 30, 2020-$9.54M-180.0%
Q1 FY2020Mar 31, 2020$7.09M+29.4%
Q4 FY2019Dec 31, 2019$4.80M-50.8%
Q3 FY2019Sep 30, 2019$12.05M+40.5%
Q2 FY2019Jun 30, 2019$11.92M+5.9%
Q1 FY2019Mar 31, 2019$5.48M–
Q4 FY2018Dec 31, 2018$9.76M+0.3%
Q3 FY2018Sep 30, 2018$8.57M-16.5%
Q2 FY2018Jun 30, 2018$11.25M-36.6%
Q1 FY2018Mar 31, 2018-$7.83M-197.8%
Q4 FY2017Dec 31, 2017$9.73M-23.6%
Q3 FY2017Sep 30, 2017$10.27M-25.0%
Q2 FY2017Jun 30, 2017$17.73M–
Q1 FY2017Mar 31, 2017$8.01M–
Q4 FY2016Dec 31, 2016$12.74M–
Q3 FY2016Sep 30, 2016$13.69M–

More Anika Therapeutics figures

See a number that looks wrong?